This grant is offered by the National Institute of Allergy and Infectious Diseases to establish a Collaborative Network for Clinical Research on Immune Tolerance. The grant aims to develop new tolerogenic approaches for treating asthma and allergic diseases, autoimmune diseases, and immune-mediated rejection of transplanted organs. Research includes clinical trials, mechanistic studies, and bioinformatics resources. Additionally, limited support is provided for product development and nonclinical studies. Applications for this grant must align with the goal of advancing immune tolerance in humans. Closing date for applications is March 7, 2013.
Opportunity ID: 205793
General Information
| Document Type:: | Grants Notice |
| Funding Opportunity Number:: | RFA-AI-12-043 |
| Funding Opportunity Title:: | Collaborative Network for Clinical Research on Immune Tolerance (UM1) |
| Opportunity Category:: | Discretionary |
| Opportunity Category Explanation:: | |
| Funding Instrument Type:: | |
| Category of Funding Activity:: | Health |
| Category Explanation:: | |
| Expected Number of Awards:: | |
| Assistance Listings Number(s):: | 93.855 — Allergy, Immunology and Transplantation Research |
| Cost Sharing or Matching Requirement:: | No |
| Version:: | Synopsis 1 |
| Posted Date:: | Nov 05, 2012 |
| Last Updated Date:: | |
| Original Closing Date for Applications:: | Mar 07, 2013 |
| Current Closing Date for Applications:: | Mar 07, 2013 |
| Archive Date:: | Apr 07, 2013 |
| Estimated Total Program Funding:: | $ 27,000,000 |
| Award Ceiling:: | $ |
| Award Floor:: | $ |
Eligibility
| Eligible Applicants:: | Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility:: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name:: | National Institutes of Health |
| Description:: | The purpose of this FOA is to solicit applications for the Collaborative Network for Clinical Research on Immune Tolerance. The major goal of this Network is to develop new tolerogenic approaches for the treatment and prevention of disease in three clinical areas: asthma and allergic diseases; autoimmune diseases; and immune-mediated rejection of transplanted solid organs, tissues and cells. The scope of research to be carried out includes: 1) the design and conduct of clinical trials at all phases to evaluate the safety and efficacy of investigational products and approaches for the induction and maintenance of immune tolerance in humans; 2) the design and conduct of mechanistic studies and the development of tolerance assays as integral components of the clinical trials undertaken, including establishing and directing a consortium of laboratories; and 3) the provision of bioinformatics, data collection, validation and analysis resources. In addition, on a limited basis, the Network may support focused product development and nonclinical studies (e.g., toxicology, pharmacology, pharmacokinetics, etc.) essential for the subsequent evaluation of promising tolerance induction approaches in humans. |
| Link to Additional Information:: | |
| Grantor Contact Information:: | If you have difficulty accessing the full announcement electronically, please contact: |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Synopsis 1 |
Package Status
Package No: 1